MA43187B1 - Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations - Google Patents

Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations

Info

Publication number
MA43187B1
MA43187B1 MA43187A MA43187A MA43187B1 MA 43187 B1 MA43187 B1 MA 43187B1 MA 43187 A MA43187 A MA 43187A MA 43187 A MA43187 A MA 43187A MA 43187 B1 MA43187 B1 MA 43187B1
Authority
MA
Morocco
Prior art keywords
antibody formulations
subcutaneous anti
subcutaneous
antibody
formulations
Prior art date
Application number
MA43187A
Other languages
English (en)
Other versions
MA43187A (fr
Inventor
Richard Jansson
Vineet Kumar
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58634408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43187(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA43187A publication Critical patent/MA43187A/fr
Publication of MA43187B1 publication Critical patent/MA43187B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations.
MA43187A 2015-11-03 2016-11-01 Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations MA43187B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250016P 2015-11-03 2015-11-03
PCT/US2016/059893 WO2017079150A1 (fr) 2015-11-03 2016-11-01 Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA43187A MA43187A (fr) 2018-09-12
MA43187B1 true MA43187B1 (fr) 2021-02-26

Family

ID=58634408

Family Applications (2)

Application Number Title Priority Date Filing Date
MA53356A MA53356B1 (fr) 2015-11-03 2016-11-01 Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA43187A MA43187B1 (fr) 2015-11-03 2016-11-01 Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA53356A MA53356B1 (fr) 2015-11-03 2016-11-01 Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations

Country Status (38)

Country Link
US (16) US10385135B2 (fr)
EP (4) EP3370770B1 (fr)
JP (7) JP7027321B2 (fr)
KR (3) KR20260053410A (fr)
CN (3) CN119950704A (fr)
AR (2) AR106582A1 (fr)
AU (3) AU2016350717B2 (fr)
BR (1) BR112018008901A8 (fr)
CA (2) CA3233159A1 (fr)
CL (1) CL2018001202A1 (fr)
CO (1) CO2018005616A2 (fr)
CR (1) CR20180251A (fr)
CY (2) CY1124004T1 (fr)
DK (2) DK3827845T3 (fr)
EA (2) EA202190808A2 (fr)
EC (1) ECSP18040758A (fr)
ES (2) ES2912729T3 (fr)
HR (2) HRP20210274T1 (fr)
HU (1) HUE053366T2 (fr)
IL (6) IL325209B1 (fr)
LT (2) LT3827845T (fr)
MA (2) MA53356B1 (fr)
MD (2) MD3827845T2 (fr)
MX (3) MX387587B (fr)
MY (1) MY202415A (fr)
NI (1) NI201800056A (fr)
PE (1) PE20181365A1 (fr)
PH (1) PH12018500950B1 (fr)
PL (2) PL3370770T3 (fr)
PT (2) PT3827845T (fr)
RS (2) RS61651B1 (fr)
SG (1) SG11201803678SA (fr)
SI (2) SI3370770T1 (fr)
SM (2) SMT202100192T1 (fr)
SV (1) SV2018005683A (fr)
TW (6) TWI910552B (fr)
WO (1) WO2017079150A1 (fr)
ZA (1) ZA201907815B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2016040294A2 (fr) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-cd38
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) * 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
WO2018002181A1 (fr) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
WO2018222718A1 (fr) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Traitement de tumeurs positives pour lag-3
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
CA3095086A1 (fr) * 2018-03-28 2019-10-03 Takeda Pharmaceutical Company Limited Administration sous-cutanee d'anticorps anti-cd38
CA3097058A1 (fr) * 2018-04-16 2019-10-24 Merck Patent Gmbh Additifs pour formulations proteiques en vue d'ameliorer la stabilite thermique
WO2019220368A1 (fr) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
CN113015805B (zh) 2018-11-13 2024-12-03 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
MX2021007047A (es) 2018-12-14 2021-10-26 Morphosys Ag Formulaciones de anticuerpos.
CA3129890A1 (fr) 2019-02-12 2020-08-20 Prothena Biosciences Limited Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux diriges contre des chaines legeres d'immunoglobuline et de la molecule de membrane cellulaire cd38 sur des c ellules productrices d'anticorps et d'autres cellules immunitaires
MA55209A (fr) 2019-03-05 2022-01-12 Prothena Biosciences Ltd Procédés de traitement de l'amylose al
WO2020185672A1 (fr) * 2019-03-08 2020-09-17 Cedars-Sinai Medical Center Agents anti-cd38 pour la désensibilisation et le traitement du rejet médié par anticorps de greffes d'organes
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
WO2020194243A1 (fr) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Compositions pharmaceutiques sous-cutanées prouvées en clinique comprenant des anticorps anti-cd38 et leurs utilisations en association avec du lénalidomide et de la dexaméthasone
WO2020194245A1 (fr) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Compositions pharmaceutiques sous-cutanées cliniquement éprouvées comprenant des anticorps anti-cd38 et leurs utilisations en association avec du bortézomib, du melphalan et de la prednisone
US20200316197A1 (en) * 2019-03-28 2020-10-08 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
US20200397896A1 (en) * 2019-04-19 2020-12-24 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
WO2020212911A2 (fr) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Polythérapies comprenant du daratumumab, du bortézomib, de la thalidomide et de la dexaméthasone et leurs utilisations
US20200330594A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
SG11202111602YA (en) * 2019-04-23 2021-11-29 Sanofi Sa Anti-cd38 antibodies and formulations
WO2020250033A1 (fr) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Polythérapies utilisant des anticorps cd-38
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
AU2020397170A1 (en) * 2019-12-05 2022-07-21 Sanofi-Aventis U.S. Llc Formulations of anti-CD38 antibodies for subcutaneous administration
MX2022008050A (es) * 2020-01-16 2022-07-27 Genmab As Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas.
TW202615652A (zh) 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
WO2021195362A1 (fr) 2020-03-26 2021-09-30 Seagen Inc. Méthodes de traitement du myélome multiple
CN115443140A (zh) * 2020-04-02 2022-12-06 苏州恒康生命科学有限公司 人ror-1抗体和抗ror-1-car-t细胞
US12636340B2 (en) * 2020-04-29 2026-05-26 Onyx Pharmaceuticals, Inc. Methods of treating multiple myeloma
BR112022023137A2 (pt) * 2020-05-15 2023-02-07 Takeda Pharmaceuticals Co Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38
CN113797161A (zh) * 2020-06-11 2021-12-17 上海宝济药业有限公司 一种重组人透明质酸酶的液体制剂及其应用
WO2022031093A1 (fr) 2020-08-07 2022-02-10 (주)알테오젠 Procédé de production d'hyaluronidase recombinant
CA3196496A1 (fr) 2020-10-23 2022-04-28 Laurence David TOMS Therapie par antagoniste de lag-3 pour le cancer du poumon
WO2022137186A1 (fr) * 2020-12-23 2022-06-30 Crispr Therapeutics Ag Traitement du cancer à l'aide d'un inhibiteur de cd38 et/ou du lénalidomide et des lymphocytes t exprimant un récepteur d'antigène chimère
WO2022141232A1 (fr) * 2020-12-30 2022-07-07 上海宝济药业有限公司 Formulation de hyaluronidase humaine recombinante et application associée
US20240197783A1 (en) 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
US11694876B2 (en) 2021-12-08 2023-07-04 Applied Materials, Inc. Apparatus and method for delivering a plurality of waveform signals during plasma processing
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
MA70850A1 (fr) * 2022-07-26 2025-10-31 Joint Stock Company "Biocad" Composition pharmaceutique d'anticorps anti-cd20 et son utilisation
WO2025188901A1 (fr) 2024-03-05 2025-09-12 Halozyme, Inc. Multithérapie utilisant des conjugués anticorps-médicament et des hyaluronidases
WO2026028163A1 (fr) 2024-08-01 2026-02-05 Janssen Biotech, Inc. Méthodes de traitement du myélome multiple indolent à haut risque
KR20260030035A (ko) * 2024-08-22 2026-03-05 (주)셀트리온 안정한 약제학적 제제
WO2026046348A1 (fr) * 2024-08-30 2026-03-05 杭州九源基因生物医药股份有限公司 Formulation pharmaceutique stable d'anticorps anti-cd38 et son utilisation
WO2026158433A1 (fr) * 2025-01-24 2026-07-30 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un anticorps anti-pd-l1 et utilisation pharmaceutique de celle-ci

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US250016A (en) 1881-11-22 Refrigerating apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
WO1989008114A1 (fr) 1988-02-25 1989-09-08 The General Hospital Corporation Procede de clonage par immunoselection rapide
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU658370B2 (en) 1990-07-13 1995-04-13 General Hospital Corporation, The CD53 cell surface antigen and use thereof
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP4233608B2 (ja) 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
ES2191827T3 (es) 1996-10-17 2003-09-16 Immunomedics Inc Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
WO2000006194A2 (fr) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion de cellules responsables du rejet d'une greffe induit par des anticorps
ATE302217T1 (de) 1997-05-02 2005-09-15 Us Gov Health & Human Serv Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
PT1256576E (pt) 2000-02-15 2005-09-30 Astellas Pharma Inc Derivados de imidazolio fundidos
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
WO2001097844A1 (fr) 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles
EP1174440A1 (fr) 2000-07-19 2002-01-23 U-BISys B.V. Un épitope exprimé sélectivement sur la molécule humaine CD38 et détecté par un fragment d'un anticorps humain de forme scFv dérivé d'une librairie "phage display"
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
US6955884B2 (en) 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
EP2330213A1 (fr) 2003-03-05 2011-06-08 Halozyme, Inc. Glycoprotéine d'hyaluronidase soluble (sHASEGP), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
KR101015034B1 (ko) 2003-04-15 2011-02-16 아스텔라스세이야쿠 가부시키가이샤 브롬화물 및 이의 결정
US7543051B2 (en) 2003-05-30 2009-06-02 Borland Software Corporation Method of non-intrusive analysis of secure and non-secure web application traffic in real-time
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1689435A4 (fr) 2003-10-22 2007-10-03 Univ Rochester Antiserum anti-thymocyte et son utilisation pour declencher l'apoptose des cellules b
PT1684805E (pt) 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
JP4712724B2 (ja) 2003-12-23 2011-06-29 クルセル ホランド ベー ヴェー ＣＤ１ａに対するヒト結合分子
EP2915820A1 (fr) 2004-02-06 2015-09-09 MorphoSys AG Anticorps humains anti-CD38 et utilisations de ceux-ci
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP2551282A3 (fr) * 2005-03-23 2013-02-13 Genmab A/S Anticorps diriges contre CD38 pour le traitement du myelome multiple
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN103145837A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
MX2008007140A (es) 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
JP2009545601A (ja) 2006-08-02 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用
WO2008073160A2 (fr) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Procédés de conversion ou d'induction d'une immunité protectrice
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
CA2681743A1 (fr) * 2007-03-22 2008-09-25 Imclone Llc Formulations d'anticorps stables
EP2626372B1 (fr) 2007-03-29 2018-03-21 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
AU2008260445A1 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
RU2491095C2 (ru) 2007-11-09 2013-08-27 Новартис Аг Применения анти-cd40-антител
WO2009062504A1 (fr) 2007-11-13 2009-05-22 Tnm Farmguard Aps Communication sécurisée entre un client et des dispositifs sur différents réseaux locaux privés utilisant les mêmes adresses de sous-réseau
EP2237798A2 (fr) 2007-12-12 2010-10-13 Imperial Innovations Limited Procédés
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
CN101970650B (zh) 2008-03-06 2017-07-25 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
BRPI0909227B8 (pt) 2008-03-25 2021-05-25 Roche Glycart Ag uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
WO2009128917A2 (fr) * 2008-04-14 2009-10-22 Halozyme, Inc. Hyaluronidases modifiées et utilisations pour traiter des maladies et des pathologies associées à l'acide hyaluronique
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EP2282769A4 (fr) 2008-04-29 2012-04-25 Abbott Lab Immunoglobulines à double domaine variable et utilisations
HUE043326T2 (hu) 2008-11-07 2019-08-28 Amgen Res Munich Gmbh Akut limfoblasztos leukémia kezelése
EP2191841A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
EP2191842A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
EP2191840A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
EP2191843A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
NZ593905A (en) 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
EP2327725A1 (fr) 2009-11-26 2011-06-01 InflaRx GmbH Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
WO2011121588A1 (fr) 2010-03-29 2011-10-06 Ben Gurion University Of The Negev Research And Development Authority Procédé et système de détection et de surveillance d'un cancer hématologique
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (fr) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Protéines hétérodimériques et leurs procédés de production et de purification
EP2580243B1 (fr) 2010-06-09 2019-10-16 Genmab A/S Anticorps dirigés contre le cd38 humain
EP2420253A1 (fr) 2010-08-20 2012-02-22 Leadartis, S.L. Synthèse de molécules polyvalentes et multifonctionnelles avec un domaine de trimérisation de collagène XV
US8877899B2 (en) 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CL2013001944A1 (es) 2010-12-30 2014-09-12 Takeda Pharmaceutical Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
US20140051662A1 (en) 2011-04-08 2014-02-20 Ab Science Treatment of multiple myeloma with masitinib
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP2561868A1 (fr) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Compositions pharmaceutiques comportant de l'hydroxychloroquine (HCQ), curcuma, pipérine/BioPérine et utilisations associées dans le domaine médical
EP2747571A4 (fr) 2011-08-24 2015-05-27 David Kerr Chimiothérapie combinée faiblement dosée
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013083140A1 (fr) 2011-12-07 2013-06-13 N.V. Nutricia Peptides de bêta-lactoglobuline pour traiter une allergie aux protéines du lait de vache
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
KR20160105535A (ko) * 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
EP2833905B1 (fr) 2012-04-04 2018-05-02 Halozyme, Inc. Combinaison de la hyaluronidase et d'un taxane ciblé de tumeur
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
HRP20171964T1 (hr) 2012-09-25 2018-02-23 Morphosys Ag Kombinacije i njihova upotreba
US9486547B2 (en) 2012-11-05 2016-11-08 Morphosys Ag Radiolabelled antibody and uses thereof
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
WO2014100740A1 (fr) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anticorps anti-ntb-a et compositions et procédés associés
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
WO2014142220A1 (fr) 2013-03-13 2014-09-18 アステラス製薬株式会社 Agent antitumoral
US20140271644A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
CA2909952C (fr) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anticorps anti-cd38 et fusions sur un interferon alpha-2b attenue
US20140356318A1 (en) 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
EP3021866A4 (fr) 2013-07-15 2017-02-22 The Board of Trustees of the Leland Stanford Junior University Utilisations médicales d'agonistes de cd38
MX373301B (es) 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
JP2016536361A (ja) 2013-11-06 2016-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (fr) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk
EP3154581B1 (fr) 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocage de cd38 à l'aide de f(ab')2 anti-cd38 pour protéger les cellules nk
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2016040294A2 (fr) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-cd38
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
MA41555A (fr) 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
EP3303397A1 (fr) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Méthodes destinées à traiter le cancer à l'aide d'anticorps anti-ox40 et d'antagonistes se liant à l'axe pd-1
CN107708734B (zh) * 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3313441B1 (fr) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38
CA2990705A1 (fr) 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methodes de traitement d'hemopathies malignes a l'aide d'une therapie d'association a base de nanoparticules comprenant un inhibiteur de mtor
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US20170121417A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
WO2018002181A1 (fr) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
WO2018108991A2 (fr) 2016-12-13 2018-06-21 Ecole Polytechnique Federale De Lausanne Méthodes de traitement de maladies du peptide bêta-amyloïde
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CA3095086A1 (fr) 2018-03-28 2019-10-03 Takeda Pharmaceutical Company Limited Administration sous-cutanee d'anticorps anti-cd38
US20190298827A1 (en) * 2018-04-03 2019-10-03 Janssen Biotech, Inc. Methods of Treating Multiple Myeloma
WO2019220368A1 (fr) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
MA53920A (fr) 2018-10-17 2021-09-15 Janssen Biotech Inc Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
CN113015805B (zh) * 2018-11-13 2024-12-03 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
WO2020170211A1 (fr) 2019-02-22 2020-08-27 Janssen Biotech, Inc. Procédés de traitement d'un myélome multiple nouvellement diagnostiqué avec une association d'un anticorps qui se lie spécifiquement à cd38, de lénalidomide et de dexaméthasone
US20200316197A1 (en) * 2019-03-28 2020-10-08 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
US20200308297A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
WO2020194245A1 (fr) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Compositions pharmaceutiques sous-cutanées cliniquement éprouvées comprenant des anticorps anti-cd38 et leurs utilisations en association avec du bortézomib, du melphalan et de la prednisone
WO2020194243A1 (fr) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Compositions pharmaceutiques sous-cutanées prouvées en clinique comprenant des anticorps anti-cd38 et leurs utilisations en association avec du lénalidomide et de la dexaméthasone
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
US20200405854A1 (en) 2019-04-19 2020-12-31 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200392242A1 (en) 2019-04-19 2020-12-17 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200397896A1 (en) 2019-04-19 2020-12-24 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
WO2020243911A1 (fr) 2019-06-04 2020-12-10 上海科技大学 Utilisations de nad+ et/ou d'inhibiteurs de nad+ et/ou d'agonistes de nad+ et leur préparation combinée
US20220275101A1 (en) 2021-02-09 2022-09-01 Janssen Biotech, Inc. Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain Amyloidosis
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors

Also Published As

Publication number Publication date
TW202612737A (zh) 2026-04-01
CN119950704A (zh) 2025-05-09
JP2026108782A (ja) 2026-06-30
MA53356A (fr) 2021-06-02
US20260139071A1 (en) 2026-05-21
TWI724048B (zh) 2021-04-11
MX2021014955A (es) 2022-02-03
PL3370770T3 (pl) 2021-07-05
AU2023237196A1 (en) 2023-10-26
US12698337B2 (en) 2026-08-04
EP4516319A2 (fr) 2025-03-05
JP7374275B2 (ja) 2023-11-06
PH12018500950A1 (en) 2018-11-12
KR20180067693A (ko) 2018-06-20
PT3827845T (pt) 2022-07-08
JP2026048792A (ja) 2026-03-17
TW201726168A (zh) 2017-08-01
HRP20220680T1 (hr) 2022-07-08
PE20181365A1 (es) 2018-08-27
RS63210B1 (sr) 2022-06-30
EP4085929A1 (fr) 2022-11-09
HRP20210274T1 (hr) 2021-06-11
EP3827845B1 (fr) 2022-03-30
US20260201056A1 (en) 2026-07-16
TW202444413A (zh) 2024-11-16
NZ780958A (en) 2025-06-27
US12637519B2 (en) 2026-05-26
WO2017079150A1 (fr) 2017-05-11
IL330397A (en) 2026-08-01
PT3370770T (pt) 2021-02-22
US20200002433A1 (en) 2020-01-02
US11708419B2 (en) 2023-07-25
CA3233159A1 (fr) 2017-05-11
AU2016350717A1 (en) 2018-05-17
JP2024010079A (ja) 2024-01-23
AR106582A1 (es) 2018-01-31
US11566079B2 (en) 2023-01-31
NZ742135A (en) 2024-10-25
US11708420B2 (en) 2023-07-25
EP3370770B1 (fr) 2021-01-20
JP2018537525A (ja) 2018-12-20
CY1124004T1 (el) 2022-05-27
JP7842070B2 (ja) 2026-04-07
EA202190808A2 (ru) 2021-12-31
US10385135B2 (en) 2019-08-20
MX2021014956A (es) 2022-02-03
JP7169396B2 (ja) 2022-11-10
TWI800341B (zh) 2023-04-21
EA201891083A1 (ru) 2018-12-28
IL330320A (en) 2026-08-01
PH12018500950B1 (en) 2023-09-20
BR112018008901A8 (pt) 2019-02-26
CA3004152A1 (fr) 2017-05-11
ECSP18040758A (es) 2018-06-30
LT3370770T (lt) 2021-04-12
MA53356B1 (fr) 2022-05-31
US20200231697A1 (en) 2020-07-23
ZA201907815B (en) 2020-12-23
US20250270342A1 (en) 2025-08-28
JP2022185004A (ja) 2022-12-13
DK3370770T3 (da) 2021-03-01
CN108472369A (zh) 2018-08-31
AR135193A1 (es) 2026-07-22
SMT202200243T1 (it) 2022-07-21
TWI910552B (zh) 2026-01-01
SG11201803678SA (en) 2018-05-30
IL325209B1 (en) 2026-07-01
NI201800056A (es) 2018-08-30
LT3827845T (lt) 2022-06-10
US20260184808A1 (en) 2026-07-02
TW202344268A (zh) 2023-11-16
MX387587B (es) 2025-03-18
CA3004152C (fr) 2024-04-16
US20260217853A1 (en) 2026-07-30
IL330031A (en) 2026-08-01
TW202245840A (zh) 2022-12-01
JP2026048791A (ja) 2026-03-17
ES2912729T3 (es) 2022-05-27
HUE053366T2 (hu) 2021-06-28
US11732051B2 (en) 2023-08-22
US20260209382A1 (en) 2026-07-23
KR20260053410A (ko) 2026-04-21
BR112018008901A2 (en) 2018-11-06
JP7027321B2 (ja) 2022-03-01
AU2025275132A1 (en) 2026-01-08
CL2018001202A1 (es) 2018-10-12
US20250388693A1 (en) 2025-12-25
US20210107991A1 (en) 2021-04-15
MD3827845T2 (ro) 2022-09-30
CO2018005616A2 (es) 2018-05-31
IL259075A (en) 2018-06-28
EP3370770A4 (fr) 2019-06-12
US20240092927A1 (en) 2024-03-21
SMT202100192T1 (it) 2021-05-07
ES2862425T3 (es) 2021-10-07
TWI838196B (zh) 2024-04-01
CR20180251A (es) 2018-08-06
IL330074A (en) 2026-08-01
JP2021119137A (ja) 2021-08-12
MD3370770T2 (ro) 2021-05-31
PL3827845T3 (pl) 2022-07-11
SV2018005683A (es) 2018-08-31
MA43187A (fr) 2018-09-12
US20170121414A1 (en) 2017-05-04
MY202415A (en) 2024-04-27
CY1125241T1 (el) 2025-03-28
RS61651B1 (sr) 2021-04-29
EP3827845A1 (fr) 2021-06-02
SI3370770T1 (sl) 2021-03-31
CN119950705A (zh) 2025-05-09
MX2018005613A (es) 2018-09-21
US20210095042A1 (en) 2021-04-01
US20260209381A1 (en) 2026-07-23
EP3370770A1 (fr) 2018-09-12
TW202144006A (zh) 2021-12-01
AU2016350717B2 (en) 2023-08-10
EP4516319A3 (fr) 2025-05-07
DK3827845T3 (da) 2022-05-23
US20260226186A1 (en) 2026-08-06
US12583936B2 (en) 2026-03-24
KR20260053090A (ko) 2026-04-20
IL325209A (en) 2026-02-01
US20200339701A1 (en) 2020-10-29
TWI760170B (zh) 2022-04-01
SI3827845T1 (sl) 2022-06-30

Similar Documents

Publication Publication Date Title
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA40576A (fr) Anticorps et immunoconjugués anti-her2
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MX377710B (es) Anticuerpos monoclonales contra bcma.
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MA44637A1 (fr) Composes hétérocycliques et leurs utilisations
MX388893B (es) Formulaciones de anticuerpos estables acuosas.
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
MA45809B1 (fr) Promédicaments de pth
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
MY205583A (en) Acid-alpha glucosidase variants and uses thereof
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MA44550B1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MA39411A (fr) Synthèse de l'énantiomère de la progestérone et ses intermédiaires
MA39355B2 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201792492A1 (ru) Aml-антигены и их применение
FR3044927B1 (fr) Emulsion magnetique reactive